Developer docs
API playgroundTry for free, no card

Search company profiles

Nanotein Technologies

Full company profile

uuid0002f6n

Namestring
Nanotein Technologies
Legal namestring
Nanotein, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Nanotein Technologies is a Berkeley, California-based biotechnology company founded in 2019 by Curtis Hodge (CEO) and Greg Hura (CSO), commercializing protein-engineering research originally developed at Lawrence Berkeley National Laboratory. The company builds cell activation and expansion reagents used in the ex vivo manufacturing of immune cell therapies, including CAR-T and NK cell products. Its proprietary NanoSpark™ platform uses self-assembling protein nanoparticles that display functional antibodies in geometrically optimized orientations to drive receptor clustering and produce higher yields of stemlike T cells. Nanotein's three core products — NanoSpark™ STEM-T (T cell activator), EVEN-T (CD4+:CD8+ ratio modulator), and GROW-NK (feeder-free NK cell activator) — are all protein-based, soluble, and filter-sterilizable, eliminating synthetic and magnetic contaminants common in legacy reagents.

The company sells research-grade reagents directly through its website and via an exclusive global distribution agreement with Sartorius Stedim Biotech, which also took a $3M minority equity stake in August 2025. cGMP-grade versions of STEM-T (targeted for 2025) and GROW-NK are being produced in partnership with Akron Bio to support clinical and commercial-scale cell therapy manufacturing. Pricing for research products ranges from $300 to $650 per unit, with unit volumes rather than enterprise contracts as the primary revenue mechanic.

Nanotein serves biopharmaceutical and biotech companies developing CAR-T and NK cell therapies, alongside academic and research institutions working on immune cell biology. The company has been recognized as a Top 10 Biotech Startup of 2021 by Life Sciences Review and a Top Emerging Biotech by QB3. As of the input data, Nanotein remains privately held with a small team (1-10 employees), strategic backers including Polaris Group (2020) and Sartorius Stedim Biotech (2025), and revenue not publicly disclosed.

Short descriptiontext

Nanotein Technologies develops protein-nanoparticle cell activation reagents (NanoSpark™ STEM-T, EVEN-T, GROW-NK) for ex vivo CAR-T and NK cell therapy manufacturing, serving biopharmaceutical developers and academic researchers with soluble, GMP-grade products distributed globally via Sartorius.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy reagents, T cell activation, NK cell expansion, CAR-T manufacturing, bioprocessing reagents
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Reagents
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research-grade Reagent Sales
TypeOne Time License
Description

Sale of NanoSpark™ research-use reagents including STEM-T, EVEN-T, and GROW-NK activators for T cell and NK cell expansion research

nanoteintech.com
2Distribution Revenue through Sartorius
TypeOne Time License
Description

Revenue generated through exclusive global distribution agreement with Sartorius Stedim Biotech for commercializing cell activator reagents

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details3 tiers
1NanoSpark™ STEM-T Soluble T Cell Activator - 2 mL
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$550.00 per unit; anti-CD3/CD28 based; GMP in production, available ~Q1 2025

nanoteintech.com
2NanoSpark™ EVEN-T Soluble T Cell Activator - 1 mL
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$300.00 per unit; first-in-class CD4+:CD8+ ratio shifting technology; GMP version in development

nanoteintech.com
3NanoSpark™ GROW-NK Soluble Activator - 2 mL
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$650.00 per unit; feeder-free NK cell activation; GMP in production, available 2025

nanoteintech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NanoSpark™
Description

Proprietary nano-scaffolding platform technology that geometrically orients antibodies for optimal immune cell activation, used across all cell activator products including STEM-T, EVEN-T, and GROW-NK.

nanoteintech.com
Core offering1 text field

Nanotein Technologies develops and sells proprietary NanoSpark-branded soluble protein nanoparticle reagents for ex vivo activation and expansion of T cells and NK cells used in cell therapy manufacturing. The portfolio includes NanoSpark STEM-T (CAR-T expansion with high stemness), NanoSpark EVEN-T (CD4+:CD8+ ratio control), and NanoSpark GROW-NK (feeder-free NK cell activation), sold as research-grade reagents today and in cGMP versions under development for clinical and commercial cell therapy manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Produces up to 2x more CD8+ TSCM cells compared to competitors
+3 more records
Product overview1 text field

Nanotein Technologies offers the NanoSpark™ platform technology for ex vivo immune cell activation and expansion in cell therapy manufacturing. The product portfolio includes three core reagent products: NanoSpark™ STEM-T (for high stemlike CD8+ T cell production), NanoSpark™ EVEN-T (for controlled CD4+:CD8+ ratio modulation), and NanoSpark™ GROW-NK (for feeder-free NK cell activation). All products use proprietary self-assembling protein nanoparticles displaying functional antibodies in geometrically optimized orientations. The company is developing cGMP versions of STEM-T and GROW-NK for commercial manufacturing scale-up.

Product and service3 records
1NanoSpark STEM-T Soluble T Cell Activator
CategoryCell Therapy Reagent / T Cell Activation
Description

Easy-to-use T cell activator reagent kit for activation and expansion of human T cells including CAR-T cells. Uses anti-CD3/CD28 antibodies on a proprietary protein nanoparticle platform to drive high stemlike CD8+ T cell production, in a soluble, all-protein-based format requiring no magnetic components. Targeted at cell therapy developers and academic researchers.

2NanoSpark EVEN-T Soluble T Cell Activator
CategoryCell Therapy Reagent / T Cell Activation
Description

First-in-class T cell activator that allows users to modulate the CD4+:CD8+ ratio in a dose-dependent manner during T cell expansion. Uses a proprietary additive to shift the CD4+:CD8+ ratio throughout expansion while maintaining excellent total T cell expansion. Targeted at cell therapy developers needing controlled T cell composition.

3NanoSpark GROW-NK Soluble Activator
CategoryCell Therapy Reagent / NK Cell Activation
Description

Feeder-free NK cell activator for ex vivo activation and expansion of human NK cells. Uses anti-NKp46 and anti-CD2 antibodies on the NanoSpark protein nanoparticle platform to drive internal signal transduction. A high performance, soluble, all-protein-based reagent designed to make traditional irradiated feeder cells obsolete. Targeted at NK cell therapy developers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-12
Description

Strategic partnership with exclusive global distribution agreement. Sartorius invested $3 million for a minority shareholding in Nanotein. Sartorius will commercialize Nanotein's NanoSpark® T cell and NK cell activator reagents designed to enhance cell therapy manufacturing processes. Companies will also jointly develop additional products for the rapidly expanding cell and gene therapy markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Partnership for cGMP production of NanoSpark® STEM-T Soluble T Cell Activator. Akron Bio, a leading supplier of critical materials and services for advanced therapies, will manufacture the GMP-grade version of the product to support commercial scale-up.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Strategic partnership established in 2020 with Polaris Group, a developer of novel cancer treatments. Polaris serves as a major investor and manufacturing partner of Nanotein. The partnership leverages Polaris's expertise in cancer therapeutics development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor to Nanotein in T cell and NK cell activation reagents for cell therapy manufacturing, including T Cell TransAct™ (soluble activator) and MACS® GMP products. Most analogous peer given overlapping product categories targeting the same CAR-T and NK cell therapy developers.

TypeBroad incumbent
Description

Major life sciences incumbent offering Dynabeads™ CD3/CD28 magnetic bead activators and CTS™ cell therapy reagent portfolio. Competes with NanoSpark across T cell activation and broader cell therapy manufacturing, with substantially larger commercial and manufacturing scale.

TypeBroad incumbent
Description

Diversified life sciences tools company offering T cell activation reagents (e.g., ImmunoCult™), cytokines, and cell therapy workflow products. Provides direct competition in T cell/NK cell expansion reagents as part of a broader portfolio.

TypeDirect peer
Description

Direct competitor in cell culture and immune cell activation reagents, including ImmunoCult™ T Cell Activators and NK cell expansion products. Comparable customer base of academic, biotech, and pharma cell therapy developers.

TypeDirect peer
Description

GMP-grade cell and gene therapy raw materials supplier including cytokines and reagents for T cell/NK cell manufacturing. Directly comparable as a focused cell therapy reagent specialist with GMP product positioning.

TypeBroad incumbent
Description

Global CDMO and cell therapy solutions provider offering cell therapy manufacturing services and select reagents. Adjacent competitor given its role in the cell therapy supply chain and growing reagent/cell therapy product offering.

TypeEmerging player
Description

Cell therapy enabling technology company focused on electroporation for cell engineering. Comparable as a cell therapy enabling platform, though focused on a different step (transfection) versus Nanotein's activation/expansion focus.

TypeOthers
Description

Strategic contract manufacturing partner of Nanotein for GMP production of STEM-T. Comparable ecosystem participant supplying cytokines and ancillary materials to advanced therapy developers; both serve the same end-customer base.

TypeBroad incumbent
Description

Large life sciences tools and bioprocessing supplier offering cell therapy workflow products and services through its broader portfolio. Competes indirectly with NanoSpark reagents via cell expansion and processing solutions.

TypeOthers
Description

Exclusive global distribution partner and minority equity investor in Nanotein. Listed as a peer because Sartorius also offers bioprocess and cell therapy products adjacent to Nanotein's reagent offerings; the relationship is a strategic commercial alliance rather than direct head-to-head competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanotein Technologies

Cell Therapy Reagentsnanoteintech.com

Nanotein Technologies develops protein-nanoparticle cell activation reagents (NanoSpark™ STEM-T, EVEN-T, GROW-NK) for ex vivo CAR-T and NK cell therapy manufacturing, serving biopharmaceutical developers and academic researchers with soluble, GMP-grade products distributed globally via Sartorius.

What Nanotein Technologies does

Nanotein Technologies is a Berkeley, California-based biotechnology company founded in 2019 by Curtis Hodge (CEO) and Greg Hura (CSO), commercializing protein-engineering research originally developed at Lawrence Berkeley National Laboratory. The company builds cell activation and expansion reagents used in the ex vivo manufacturing of immune cell therapies, including CAR-T and NK cell products. Its proprietary NanoSpark™ platform uses self-assembling protein nanoparticles that display functional antibodies in geometrically optimized orientations to drive receptor clustering and produce higher yields of stemlike T cells. Nanotein's three core products — NanoSpark™ STEM-T (T cell activator), EVEN-T (CD4+:CD8+ ratio modulator), and GROW-NK (feeder-free NK cell activator) — are all protein-based, soluble, and filter-sterilizable, eliminating synthetic and magnetic contaminants common in legacy reagents.

The company sells research-grade reagents directly through its website and via an exclusive global distribution agreement with Sartorius Stedim Biotech, which also took a $3M minority equity stake in August 2025. cGMP-grade versions of STEM-T (targeted for 2025) and GROW-NK are being produced in partnership with Akron Bio to support clinical and commercial-scale cell therapy manufacturing. Pricing for research products ranges from $300 to $650 per unit, with unit volumes rather than enterprise contracts as the primary revenue mechanic.

Nanotein serves biopharmaceutical and biotech companies developing CAR-T and NK cell therapies, alongside academic and research institutions working on immune cell biology. The company has been recognized as a Top 10 Biotech Startup of 2021 by Life Sciences Review and a Top Emerging Biotech by QB3. As of the input data, Nanotein remains privately held with a small team (1-10 employees), strategic backers including Polaris Group (2020) and Sartorius Stedim Biotech (2025), and revenue not publicly disclosed.

Nanotein Technologies firmographics

Firmographics
Name
Nanotein Technologies
Legal name
Nanotein, Inc.
Website
https://nanoteintech.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Nanotein Technologies develops protein-nanoparticle cell activation reagents (NanoSpark™ STEM-T, EVEN-T, GROW-NK) for ex vivo CAR-T and NK cell therapy manufacturing, serving biopharmaceutical developers and academic researchers with soluble, GMP-grade products distributed globally via Sartorius.
Ownership category
akta.pro rank

Nanotein Technologies industry classification

Industry
Product category
Cell Therapy Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy reagents
  • T cell activation
  • NK cell expansion
  • CAR-T manufacturing
  • Bioprocessing reagents

Where Nanotein Technologies is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nanotein Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Research-grade Reagent Sales: Sale of NanoSpark™ research-use reagents including STEM-T, EVEN-T, and GROW-NK activators for T cell and NK cell expansion research
  2. Distribution Revenue through Sartorius: Revenue generated through exclusive global distribution agreement with Sartorius Stedim Biotech for commercializing cell activator reagents

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNanoSpark™ STEM-T Soluble T Cell Activator - 2 mL
Unit PricingPay-as-you-goNanoSpark™ EVEN-T Soluble T Cell Activator - 1 mL
Unit PricingPay-as-you-goNanoSpark™ GROW-NK Soluble Activator - 2 mL

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Nanotein Technologies product offering

Product offering

Core offering

Nanotein Technologies develops and sells proprietary NanoSpark-branded soluble protein nanoparticle reagents for ex vivo activation and expansion of T cells and NK cells used in cell therapy manufacturing. The portfolio includes NanoSpark STEM-T (CAR-T expansion with high stemness), NanoSpark EVEN-T (CD4+:CD8+ ratio control), and NanoSpark GROW-NK (feeder-free NK cell activation), sold as research-grade reagents today and in cGMP versions under development for clinical and commercial cell therapy manufacturing.

Product overview

Nanotein Technologies offers the NanoSpark™ platform technology for ex vivo immune cell activation and expansion in cell therapy manufacturing. The product portfolio includes three core reagent products: NanoSpark™ STEM-T (for high stemlike CD8+ T cell production), NanoSpark™ EVEN-T (for controlled CD4+:CD8+ ratio modulation), and NanoSpark™ GROW-NK (for feeder-free NK cell activation). All products use proprietary self-assembling protein nanoparticles displaying functional antibodies in geometrically optimized orientations. The company is developing cGMP versions of STEM-T and GROW-NK for commercial manufacturing scale-up.

Differentiator

Problem solved

Functional benefit

Brands

  • NanoSpark™: Proprietary nano-scaffolding platform technology that geometrically orients antibodies for optimal immune cell activation, used across all cell activator products including STEM-T, EVEN-T, and GROW-NK.

Products and services

  • NanoSpark STEM-T Soluble T Cell Activator Easy-to-use T cell activator reagent kit for activation and expansion of human T cells including CAR-T cells. Uses anti-CD3/CD28 antibodies on a proprietary protein nanoparticle platform to drive high stemlike CD8+ T cell production, in a soluble, all-protein-based format requiring no magnetic components. Targeted at cell therapy developers and academic researchers.
  • NanoSpark EVEN-T Soluble T Cell Activator First-in-class T cell activator that allows users to modulate the CD4+:CD8+ ratio in a dose-dependent manner during T cell expansion. Uses a proprietary additive to shift the CD4+:CD8+ ratio throughout expansion while maintaining excellent total T cell expansion. Targeted at cell therapy developers needing controlled T cell composition.
  • NanoSpark GROW-NK Soluble Activator Feeder-free NK cell activator for ex vivo activation and expansion of human NK cells. Uses anti-NKp46 and anti-CD2 antibodies on the NanoSpark protein nanoparticle platform to drive internal signal transduction. A high performance, soluble, all-protein-based reagent designed to make traditional irradiated feeder cells obsolete. Targeted at NK cell therapy developers.

Quantifiable outcome

  • Produces up to 2x more CD8+ TSCM cells compared to competitors
  • +3 more outcomes

Companies that use Nanotein Technologies

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Nanotein Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nanotein Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Sartorius Stedim BiotechflagshipChannel Partner/ Reseller/ Distributor · 12 August 2025Strategic partnership with exclusive global distribution agreement. Sartorius invested $3 million for a minority shareholding in Nanotein. Sartorius will commercialize Nanotein's NanoSpark® T cell and NK cell activator reagents designed to enhance cell therapy manufacturing processes. Companies will also jointly develop additional products for the rapidly expanding cell and gene therapy markets.
  • Akron BiocoreStrategic or Co-development Partner · 8 October 2024Partnership for cGMP production of NanoSpark® STEM-T Soluble T Cell Activator. Akron Bio, a leading supplier of critical materials and services for advanced therapies, will manufacture the GMP-grade version of the product to support commercial scale-up.
  • Polaris GroupcoreStrategic or Co-development Partner · 1 January 2020Strategic partnership established in 2020 with Polaris Group, a developer of novel cancer treatments. Polaris serves as a major investor and manufacturing partner of Nanotein. The partnership leverages Polaris's expertise in cancer therapeutics development.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Nanotein Technologies competitors and assessment

Company assessment

Direct peers

  • Miltenyi Biotec: Direct competitor to Nanotein in T cell and NK cell activation reagents for cell therapy manufacturing, including T Cell TransAct™ (soluble activator) and MACS® GMP products. Most analogous peer given overlapping product categories targeting the same CAR-T and NK cell therapy developers.
  • STEMCELL Technologies: Direct competitor in cell culture and immune cell activation reagents, including ImmunoCult™ T Cell Activators and NK cell expansion products. Comparable customer base of academic, biotech, and pharma cell therapy developers.
  • CellGenix: GMP-grade cell and gene therapy raw materials supplier including cytokines and reagents for T cell/NK cell manufacturing. Directly comparable as a focused cell therapy reagent specialist with GMP product positioning.

Broad incumbents

  • Thermo Fisher Scientific: Major life sciences incumbent offering Dynabeads™ CD3/CD28 magnetic bead activators and CTS™ cell therapy reagent portfolio. Competes with NanoSpark across T cell activation and broader cell therapy manufacturing, with substantially larger commercial and manufacturing scale.
  • Bio-Techne: Diversified life sciences tools company offering T cell activation reagents (e.g., ImmunoCult™), cytokines, and cell therapy workflow products. Provides direct competition in T cell/NK cell expansion reagents as part of a broader portfolio.
  • Lonza: Global CDMO and cell therapy solutions provider offering cell therapy manufacturing services and select reagents. Adjacent competitor given its role in the cell therapy supply chain and growing reagent/cell therapy product offering.
  • Cytiva (Danaher): Large life sciences tools and bioprocessing supplier offering cell therapy workflow products and services through its broader portfolio. Competes indirectly with NanoSpark reagents via cell expansion and processing solutions.

Emerging players

  • MaxCyte: Cell therapy enabling technology company focused on electroporation for cell engineering. Comparable as a cell therapy enabling platform, though focused on a different step (transfection) versus Nanotein's activation/expansion focus.

Others

  • Akron Bio: Strategic contract manufacturing partner of Nanotein for GMP production of STEM-T. Comparable ecosystem participant supplying cytokines and ancillary materials to advanced therapy developers; both serve the same end-customer base.
  • Sartorius Stedim Biotech: Exclusive global distribution partner and minority equity investor in Nanotein. Listed as a peer because Sartorius also offers bioprocess and cell therapy products adjacent to Nanotein's reagent offerings; the relationship is a strategic commercial alliance rather than direct head-to-head competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nanotein Technologies social profiles

Digital presence

Nanotein Technologies compliance and trust

Trust signal

Compliance1 record

Nanotein Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanotein Technologies leadership team

Management profile

Number of profiles

Profiles5 records

Nanotein Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanotein Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanotein Technologies

What does Nanotein Technologies do?

Nanotein Technologies develops and sells proprietary NanoSpark-branded soluble protein nanoparticle reagents for ex vivo activation and expansion of T cells and NK cells used in cell therapy manufacturing. The portfolio includes NanoSpark STEM-T (CAR-T expansion with high stemness), NanoSpark EVEN-T (CD4+:CD8+ ratio control), and NanoSpark GROW-NK (feeder-free NK cell activation), sold as research-grade reagents today and in cGMP versions under development for clinical and commercial cell therapy manufacturing.

Is Nanotein Technologies a public or private company?

Nanotein Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanotein Technologies founded?

Nanotein Technologies was founded in 2019. It employs 1 to 10 people.

Where is Nanotein Technologies based?

Nanotein Technologies is headquartered in Berkeley, United States, in the North America region.

How does Nanotein Technologies make money?

Two revenue lines are on record. Research-grade Reagent Sales are the primary driver. The others are distribution Revenue through Sartorius.

Who are Nanotein Technologies's main competitors?

Direct peers on record are Miltenyi Biotec, STEMCELL Technologies and CellGenix. Broad incumbents are Thermo Fisher Scientific, Bio-Techne, Lonza and Cytiva (Danaher). MaxCyte is listed as an emerging player. Others are Akron Bio and Sartorius Stedim Biotech.

Does Nanotein Technologies have an API?

No public API is recorded for Nanotein Technologies.

What industry is Nanotein Technologies in?

Nanotein Technologies's product category is Cell Therapy Reagents. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Towards HealthcareCell and Gene Therapy Tools and Reagents Top Companies and Strategic InvolvementsThe global cell and gene therapy tools and reagents market reached US$ 11.12 billion in 2025 and is projected to grow to approximately US$ 27.3 billion by 2034, expanding at a CAGR of 10.76%. Notable recent developments include Sartorius Stedim Biotech investing $3 million in Nanotein Technologies for its NanoSpark platform, and Hologen providing $430 million in funding to MeiraGTx for the development of an investigational AAV-GAD gene therapy for Parkinson's disease. Other active developments include product launches by CellFE and Asimov, and a collaboration between CTMC and Syenex to expand lentiviral and retroviral vector manufacturing platforms.ContractpharmaSartorius Stedim Biotech, Nanotein Technologies to Advance Cell Therapy ManufacturingSartorius Stedim Biotech and Nanotein Technologies entered a manufacturing and distribution partnership, with Sartorius investing up to $3 million in a minority stake. Sartorius will exclusively distribute Nanotein's NanoSpark soluble T cell and NK cell activators worldwide. The companies will also collaborate to develop additional product offerings for cell and gene therapy markets.BioSpaceSartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy ManufacturingSartorius Stedim Biotech and Nanotein Technologies have formed a strategic partnership, with Sartorius investing up to $3 million in a minority shareholding in the biotech start-up. Under an exclusive global distribution agreement, Sartorius will commercialize Nanotein's NanoSpark® T cell and NK cell activator reagents designed to enhance cell therapy manufacturing processes. The companies will also jointly develop additional products for the rapidly expanding cell and gene therapy markets.SartoriusSartorius Stedim Biotech and Nanotein Technologies partner to advance cell therapy manufacturingSartorius Stedim Biotech and Nanotein Technologies partnered, with Sartorius investing up to $3 million in a minority stake. The agreement gives Sartorius exclusive worldwide distribution of Nanotein's NanoSpark soluble T cell and NK cell activators. The companies will also co-develop new products using the NanoSpark platform.NanoteintechNanotein Raises Series A Funding to Bring cGMP Products to MarketNanotein has closed a Series A funding round to support the market launch of its cGMP NanoSpark STEM-T Soluble T Cell Activator and the manufacturing ramp-up of NanoSpark GROW-NK. The company will also use the capital to finalize the development of NanoSpark EVEN-T and expand its workforce.